Faeth Therapeutics rises after FDA grants fast-track status for cancer drug

Faeth Therapeutics

17/08/2026 13:18

** Shares of cancer-drug developer Faeth Therapeutics FTH.O rise 2% to $33 premarket 
** Co says the U.S. FDA has granted fast-track status to its experimental two-drug treatment PIKTOR, in combination with chemotherapy, for certain patients with advanced or recurring endometrial cancer, a type of cancer that starts in the inner lining of the uterus 
** FDA's fast-track tag is meant to speed up the development and review of treatments for serious diseases with unmet medical needs
** PIKTOR combines the oral drugs sapanisertib and serabelisib, which are designed to block cancer-growth signals, and is being tested in patients whose cancer has worsened after prior chemotherapy and immunotherapy
** Co expects results from an ongoing mid-stage study by year-end 2026
**  As of last close, FTH up 203.1% YTD  

 (Reporting by Kunal Das in Bengaluru)
 ((Kunal.Das2@thomsonreuters.com;))